Provenance Record

830-word News piece with clean Overview / What We Know / What We Don't Know / Why It Matters structure. Dense, well-organized bulleted list of clinical and safety specifics with inline per-claim citations — a strong example of the house style. No sensationalism; appropriately caveats the unknowns (pricing, payer uptake).

All 6 sources fetched successfully (HTTP 200, sha256 of each decompressed snapshot verified against manifest.json). (1) source-0 PR Newswire / Eisai (302824254): confirms sBLA approval for once-weekly SC initiation dose, 500 mg as two 250 mg injections in ~15 seconds each, MCI/mild-dementia indication, 360 mg maintenance after 18 months IV/SC, 94% autoinjector ease-of-use, late-August 2026 launch via specialty pharmacy, Howard Fillit quote verbatim, full ARIA/ICH safety label. Does NOT contain any mention of an FDA review-period extension. (2) source-1 PR Newswire / BioArctic (302824479): confirms same approval facts from BioArctic's release; Gunilla Osswald quote verbatim ('This approval represents another important step forward in the treatment of Alzheimer's disease.' / 'By providing a new administration option from the start of treatment, patients, caregivers and healthcare professionals gain greater flexibility in how therapy is delivered.'). (3) source-2 GlobeNewswire (AAIC clinical data, July 12, 2026): confirms 104% exposure ratio (90% CI 99.1%-109%) verbatim, the 'driven by lecanemab exposure rather than route of administration' quote verbatim, 1.4% anti-drug antibody incidence with no neutralizing antibodies, and patient-satisfaction ranges (75%-97% satisfaction, 83%-97% convenience, 92%-100% willingness to recommend) verbatim. (4) source-3 PR Newswire / ADDF: confirms Laura Nisenbaum quote verbatim, Isobel Coleman 'inflection point' quote verbatim, ~75% of pipeline on non-amyloid pathways ('nearly 75%' in source vs '75%' in article — immaterial rounding, not in quote marks), $400M/792 programs/21 countries figures, and the '~15 seconds vs hour-long IV infusions' framing verbatim. (5) source-4 StockTitan: full republication of the Eisai press release plus prescribing-information safety label; confirms all ARIA figures (21% vs 9% overall, ARIA-E 13% vs 2%, ARIA-H 17% vs 9%, symptomatic ARIA 3%, serious 0.7%) and the ApoE ε4 homozygote/heterozygote/noncarrier ARIA rates (45%/19%/13%) verbatim. (6) source-5 BioSpace: confirms the same core approval facts and Howard Fillit quote verbatim, BUT the article's bracketed quote on MCI ('the earliest symptomatic stage, characterized by subtle symptoms like forgetfulness and confusion') is a paraphrase of BioSpace's actual sentence ('the earliest symptomatic stage of Alzheimer's disease and can appear with subtle symptoms such as forgetfulness, confusion, or feeling at a loss for words') rather than a verbatim quote — flagged as a finding above. Bidirectional source check: every URL cited in the body appears in article.sources and vice versa; no orphan sources.

Every numeric specific I checked (500 mg initiation / two 250 mg injections / ~15 seconds; 360 mg maintenance after 18 months; 94% ease-of-use; 104% exposure ratio with 99.1%-109% CI; 1.4% ADA incidence; 75%-97%/83%-97%/92%-100% satisfaction ranges; full ARIA/ICH percentages; ApoE ε4 45%/19%/13%; ~$400M/792 programs/21 countries; late-August 2026 launch) traces verbatim to a cited snapshot. Two issues found and detailed in findings: (1) the 'roughly two months after the FDA had extended its review period' clause in the Overview lead is not supported by any of the 6 cited sources — this is a fabricated/unverifiable regulatory-timeline detail tacked onto an otherwise well-sourced lead sentence; the lead's core claim (that the FDA approved the SC starting dose on July 13, 2026) remains accurate and independently verified across 4 of the 6 sources. (2) the BioSpace-attributed MCI quote is a paraphrase presented as verbatim.

Publish with a two-item corrections record. This is a well-sourced, well-organized News piece on a genuine regulatory event, verified against 6 independently reachable primary/wire sources with high claim fidelity; the two flagged issues are narrow, subordinate, and fully correctable in public without misleading readers about the substance of the story.